



Adherium announces the appointment of Lou Panaccio to the Board with Matt McNamara stepping down

Melbourne, Australia – 25 February 2022: Adherium Limited (“Adherium” or “the Company”; ASX: ADR), a provider of integrated digital health solutions and a world leader in connected respiratory medical devices, announces the appointment of Mr Lou Panaccio as a Non-executive director of Adherium with Mr Matthew McNamara stepping down as a Non-executive Director.

James Ward-Lilley, Chairman of Adherium commented “I am very pleased to welcome Lou to the Adherium Board. He brings more than 30 years of leadership experience in healthcare services, ASX and NASDAQ listings, and has extensive global commercial experience including in the United States.

The Board and I would also like to thank Matt for his contribution as an Adherium director. Matt has been a strong supporter of Adherium having been a Non-executive Director of the Company prior to its ASX listing and subsequently rejoining the Board in October 2019. Matt has brought his financial and business experience to Board as the business restructured and re-established its strategy and has been an active member of both the Audit & Risk and Nomination & Remuneration Committees”

- ENDS -



About Adherium (ASX: ADR)

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management.

The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease.

Learn more at www.adherium.com

This ASX announcement was approved and authorised for release by the Board of Adherium.

Enquiries: WE Communications
WE-AUAdherium@we-worldwide.com

Appendix A: Lou Panaccio's Biography



Mr Panaccio is a Chartered Accountant with extensive executive management experience in business and healthcare services.

Mr Panaccio is currently on the boards of ASX and NASDAQ listed Avita Therapeutics Inc. (Non-executive Chairman from July 2014), ASX50 company Sonic Healthcare Limited, one of the world's largest medical diagnostics companies (Non-executive Director from June 2015), and ASX-listed Rhythm Biosciences Limited (Non-executive Director from August 2017).

He is also a Non-executive Director of Unison Housing Limited, VGI Health Technology Limited, NeuralDX Limited (Non-executive Chairman from March 2019) and Haemokinesis Limited (from July 2021).

Mr Panaccio was the Chief Executive Officer and Executive Director of Melbourne Pathology for ten years to 2001, the Chief Executive Officer of Monash IVF until 2009 and the Executive Chairman of Health Networks Australia until 2017. He was also a Non-executive Director of ASX-listed Genera Biosystems Limited from November 2010 until 28 June 2019 (Chairman from July 2011 until 28 June 2019).

Mr Panaccio holds a Bachelor of Economics from Monash University and is a Member of the Australian Institute of Company Directors.